Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04745689 · ClinicalTrials.gov registry record · Phase 2

Study of AZD2811 + Durvalumab in ES-SCLC

A Phase 2 study of Small-cell Lung Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
31
Enrollment target
12
Study locations

NCT04745689 is a Phase 2 study of Small-cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 31 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04745689, a Phase 2 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
31 participants
Enrollment target
12
Study locations

Study Summary

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Etoposide
  • DRUG Durvalumab
  • DRUG AZD2811

Study Locations (12)

Other

  • Research Site - Bydgoszcz
  • Research Site - Olsztyn
  • Research Site - Poznan
  • Research Site - Cheongju-si
  • Research Site - Jinju
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seville
  • Research Site - Valencia

Michigan

  • Research Site - Grand Rapids

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2021-02-23
Est. Completion 2026-12-01
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04745689

The ClinicalTrials.gov registry entry for NCT04745689 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04745689 reports 12 study locations spanning 2 distinct geographic areas - top geographies include Other, Michigan.

Frequently Asked Questions

What is clinical trial NCT04745689 about?

NCT04745689 is a clinical study titled "Study of AZD2811 + Durvalumab in ES-SCLC". A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stag...

What is the current status of trial NCT04745689?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2021-02-23. Estimated completion is 2026-12-01.

What conditions does trial NCT04745689 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT04745689?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Durvalumab (DRUG), AZD2811 (DRUG).

Who is sponsoring clinical trial NCT04745689?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04745689 being conducted?

This trial has 12 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.